Mike Kratky
Stock Analyst at Leerink Partners
(3.36)
# 940
Out of 4,784 analysts
27
Total ratings
42.11%
Success rate
33.15%
Average return
Main Sectors:
Stocks Rated by Mike Kratky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BBNX Beta Bionics | Initiates: Outperform | $28 | $11.67 | +139.93% | 1 | Feb 24, 2025 | |
| TXG 10x Genomics | Downgrades: Market Perform | $25 → $12 | $9.13 | +31.51% | 2 | Feb 13, 2025 | |
| DXCM DexCom | Maintains: Outperform | $90 → $87 | $67.72 | +28.47% | 2 | Oct 25, 2024 | |
| INSP Inspire Medical Systems | Maintains: Market Perform | $167 → $197 | $156.15 | +26.16% | 2 | Sep 10, 2024 | |
| PEN Penumbra | Initiates: Outperform | $263 | $266.91 | -1.46% | 1 | Sep 3, 2024 | |
| TNDM Tandem Diabetes Care | Upgrades: Outperform | $34 → $45 | $19.32 | +132.98% | 2 | Apr 25, 2024 | |
| NPCE NeuroPace | Initiates: Outperform | $22 | $11.87 | +85.34% | 1 | Jan 30, 2024 | |
| PODD Insulet | Initiates: Outperform | $184 | $257.14 | -28.44% | 1 | Oct 16, 2023 | |
| VCEL Vericel | Initiates: Outperform | $42 | $44.36 | -5.32% | 1 | Oct 16, 2023 | |
| ISRG Intuitive Surgical | Initiates: Outperform | $342 | $489.37 | -30.11% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $75 | $70.95 | +5.71% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $37 | $59.37 | -37.68% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $18.40 | -51.09% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $325 → $50 | $3.47 | +1,340.92% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $45 | $1.51 | +2,880.13% | 2 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $145 → $315 | $325.85 | -3.33% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $26 → $31 | $29.47 | +5.21% | 2 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $18.23 | -23.20% | 1 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $40 | $14.50 | +175.96% | 1 | Aug 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $48 | $1.20 | +3,916.74% | 1 | Aug 11, 2022 |
Beta Bionics
Feb 24, 2025
Initiates: Outperform
Price Target: $28
Current: $11.67
Upside: +139.93%
10x Genomics
Feb 13, 2025
Downgrades: Market Perform
Price Target: $25 → $12
Current: $9.13
Upside: +31.51%
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $90 → $87
Current: $67.72
Upside: +28.47%
Inspire Medical Systems
Sep 10, 2024
Maintains: Market Perform
Price Target: $167 → $197
Current: $156.15
Upside: +26.16%
Penumbra
Sep 3, 2024
Initiates: Outperform
Price Target: $263
Current: $266.91
Upside: -1.46%
Tandem Diabetes Care
Apr 25, 2024
Upgrades: Outperform
Price Target: $34 → $45
Current: $19.32
Upside: +132.98%
NeuroPace
Jan 30, 2024
Initiates: Outperform
Price Target: $22
Current: $11.87
Upside: +85.34%
Insulet
Oct 16, 2023
Initiates: Outperform
Price Target: $184
Current: $257.14
Upside: -28.44%
Vericel
Oct 16, 2023
Initiates: Outperform
Price Target: $42
Current: $44.36
Upside: -5.32%
Intuitive Surgical
Oct 16, 2023
Initiates: Outperform
Price Target: $342
Current: $489.37
Upside: -30.11%
Oct 16, 2023
Initiates: Market Perform
Price Target: $75
Current: $70.95
Upside: +5.71%
Oct 16, 2023
Initiates: Outperform
Price Target: $37
Current: $59.37
Upside: -37.68%
Oct 16, 2023
Initiates: Outperform
Price Target: $9
Current: $18.40
Upside: -51.09%
Aug 15, 2023
Downgrades: Market Perform
Price Target: $325 → $50
Current: $3.47
Upside: +1,340.92%
Jan 24, 2023
Maintains: Outperform
Price Target: $33 → $45
Current: $1.51
Upside: +2,880.13%
Dec 20, 2022
Maintains: Outperform
Price Target: $145 → $315
Current: $325.85
Upside: -3.33%
Dec 15, 2022
Maintains: Market Perform
Price Target: $26 → $31
Current: $29.47
Upside: +5.21%
Nov 4, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $18.23
Upside: -23.20%
Aug 15, 2022
Maintains: Outperform
Price Target: $32 → $40
Current: $14.50
Upside: +175.96%
Aug 11, 2022
Maintains: Outperform
Price Target: $49 → $48
Current: $1.20
Upside: +3,916.74%